Atara Biotherapeutics (NASDAQ:ATRA – Get Rating) and Taysha Gene Therapies (NASDAQ:TSHA – Get Rating) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Insider and Institutional Ownership
34.3% of Taysha Gene Therapies shares are owned by institutional investors. 4.0% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 42.4% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Get Atara Biotherapeutics alerts:Analyst Recommendations
This is a breakdown of current recommendations and price targets for Atara Biotherapeutics and Taysha Gene Therapies, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atara Biotherapeutics | 2 | 2 | 2 | 0 | 2.00 |
| Taysha Gene Therapies | 0 | 1 | 10 | 0 | 2.91 |
Risk & Volatility
Atara Biotherapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500.Comparatively, Taysha Gene Therapies has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
Earnings & Valuation
This table compares Atara Biotherapeutics and Taysha Gene Therapies' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atara Biotherapeutics | $20.34 million | 22.20 | -$340.14 million | ($2.47) | -1.93 |
| Taysha Gene Therapies | N/A | N/A | -$174.52 million | ($4.11) | -0.57 |
Taysha Gene Therapies has lower revenue, but higher earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Atara Biotherapeutics and Taysha Gene Therapies' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atara Biotherapeutics | -348.49% | -125.38% | -71.22% |
| Taysha Gene Therapies | N/A | -338.37% | -101.42% |
Summary
Taysha Gene Therapies beats Atara Biotherapeutics on 9 of the 13 factors compared between the two stocks.
About Atara Biotherapeutics
(Get Rating)
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
About Taysha Gene Therapies
(Get Rating)
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.